Common Shares Outstanding: The number of class A shares currently held by investors.
CytoMed Therapeutics Limited (GDTC) had Common Shares Outstanding of 11.94M for the most recently reported fiscal quarter, ending 2026-06-30.
| Income Statement Financials | |
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
| Balance Sheet Financials | |
$2.50B |
|
$2.82B |
|
$2.92B |
|
$5.42B |
|
$945.88M |
|
$302.69M |
|
$302.69M |
|
$1.25B |
|
$4.17B |
|
$4.09B |
|
$4.17B |
|
|
Common Shares Outstanding |
11.94M |
| Cash Flow Statement Financials | |
$-1.27B |
|
$34.84M |
|
$744.66M |
|
$1.62B |
|
$1.13B |
|
$-492.02M |
|
$11.54M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|